Acura Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
32 Pages - GMD12100
$1,500.00

Summary

Global Markets Direct’s, ‘Acura Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Acura Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Acura Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Acura Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Acura Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Acura Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Acura Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Acura Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Acura Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Acura Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acura Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Acura Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Acura Pharmaceuticals, Inc. Snapshot 5
Acura Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Acura Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Acura Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Acura Pharmaceuticals, Inc. - Pipeline Products Glance 12
Acura Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Acura Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Discovery Products/Combination Treatment Modalities 13
Acura Pharmaceuticals, Inc. - Drug Profiles 14
(hydrocodone bitartrate + acetaminophen) 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
(oxycodone + acetaminophen) 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
hydromorphone IR 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
methadone IR 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
morphine sulfate IR 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
oxymorphone IR 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
tramadol hydrochloride IR 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Acura Pharmaceuticals, Inc. - Pipeline Analysis 21
Acura Pharmaceuticals, Inc. - Pipeline Products by Target 21
Acura Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 23
Acura Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 24
Acura Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 25
Acura Pharmaceuticals, Inc. - Recent Pipeline Updates 26
Acura Pharmaceuticals, Inc. - Company Statement 27
Acura Pharmaceuticals, Inc. - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Acura Pharmaceuticals, Inc., Key Information 5
Acura Pharmaceuticals, Inc., Key Facts 5
Acura Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Acura Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Acura Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Acura Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Acura Pharmaceuticals, Inc. - Phase II, 2014 12
Acura Pharmaceuticals, Inc. - Discovery, 2014 13
Acura Pharmaceuticals, Inc. - Pipeline by Target, 2014 22
Acura Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 23
Acura Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 24
Acura Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 25
Acura Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 26
Acura Pharmaceuticals, Inc., Subsidiaries 30

List of Figures
Acura Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014 7
Acura Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Acura Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Acura Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014 21
Acura Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014 23
Acura Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014 24
Acura Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 25

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax